Celltrion presented new research that demonstrates that a formulation of its infliximab biosimilar intended for subcutaneous administration is comparable to the intravenously administered option. The phase 1 study compared the subcutaneous formulation—which can be self-administered—with the FDA-approved intravenous formulation in patients with active Crohn disease (CD).
At Digestive Disease Week, held in Washington, DC, Celltrion presented new research that demonstrates that a formulation of its infliximab biosimilar, CT-P13 (sold in the United States as Inflectra and in the European Union as Remsima), intended for subcutaneous administration is comparable to the intravenously administered option.
The phase 1 study compared the subcutaneous formulation—which can be self-administered—with the FDA-approved intravenous formulation in patients with active Crohn disease (CD) as measured by a Crohn Disease Activity Index (CDAI) score of 220 to 450.
In total, 44 patients were randomized to 4 treatment cohorts after having been treated with intravenous CT-P13 at a dose of 5 mg/kg at weeks 0 and 2.
The first cohort continued treatment with the same dose of intravenous CT-P13 (at weeks 6, 14, 22, and 30), while the second, third, and fourth cohorts were treated with subcutaneous doses of CT-P13 at doses of 120 mg, 180 mg, and 240 mg, respectively, injected biweekly up to week 30.
Overall, the number of patients who achieved CDAI-70 (a decrease in baseline CDAI score of at least 70 points) at week 30 was similar across the 4 cohorts, at 8 (66.7%), 9 (81.8%), 10 (83.3%), and 5 (71.4%), respectively. The number of patients who achieved clinical remission at week 30 was also similar across the 4 cohorts, at 7 (58.3%), 9 (81.8%), 7 (58.3%), and 5 (71.4%), respectively.
One patient each from the first and fourth cohorts experienced hypersensitivity, but only the patient who received the intravenous formulation of infliximab tested positive for anti-drug antibodies. All injection-site reactions were grade 1 or grade 2 in intensity.
The study’s authors say that pharmacokinetic and pharmacodynamic modeling based on the comparable efficacy and safety results suggest that the subcutaneous and intravenous doses of CT-P13 are similar.
Hyoung-Ki Kim, vice chairman of Celltrion Healthcare, said in a statement that the results for the subcutaneous product are “…a significant milestone for Celltrion Healthcare and our partners. This kind of innovation will enable us to differentiate our portfolio and provide a more convenient and accessible treatment administration option to patients with chronic conditions like [inflammatory bowel disease] in the United States.”
Currently, there are no subcutaneously administered infliximab products available in the US marketplace. If eventually approved, the subcutaneous biosimilar product could allow patients greater flexibility in their treatment options for inflammatory diseases.
Reference
Schreiber S, Jang BI, Borzan V, et al. Novel formulation of CT-P13 (infliximab biosimilar) for subcutaneous administration: initial results from a phase 1 open-label randomized controlled trial in patients with active Crohn’s disease. Gastroenterology. 2018;154(6):S-1371. doi: 10.1016/S0016-5085(18)34477-9.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Study: Biosimilar Use, Dose Rounding Produce More Cost Savings Than Either Strategy Alone
November 18th 2023A retrospective study of New England patients receiving trastuzumab or bevacizumab found that combining dose rounding and biosimilar use resulted in greater cost savings than either strategy alone.